SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorNanfang Hospital, Southern Medical University
About this trial
In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury. The present study aimed to establish an early diagnosis warning model for acute-on-chronic liver failure (ACLF) by SSM and investigate the effect of dynamic changes in SSM on the short-term prognosis (28-day, 90-day morbidity and mortality) of inpatients with CLD and acute liver injury.
Eligibility criteria
Qualifiers
Age between 18 years and 80 years
Chronic liver diseases regardless of etiology
Acute liver injury with total bilirubin ≥ 3 mg/dl regardless of inducement
Disqualifiers
Prior surgery of liver diseases before enrollment such as liver transplantation, transjugular intrahepatic portosystemic shunt (TIPS), splenectomy and partial splenic embolization
Severe extrahepatic diseases such as chronic obstructive pulmonary disease level IV, chronic kidney disease with end-stage renal failure, myocardial infarction within 3 months before admission
Receiving Immunosuppressive drugs for reasons rather than chronic liver diseases
Diagnosis of hepatocellular carcinoma or other non-liver malignancies during screening period
Trial design
Treatments tested in this trial
- FibroScan® Expert 630
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov